SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : TheraTech (THRT)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Robert A. Gleason who wrote (37)3/14/1997 11:50:00 AM
From: Rick Strange   of 125
 
Robert,

For most Biotech stocks, P.E. isn't a very valuable tool because most have negative earnings. TheraTech is an exception to that rule. Last years earnings were $.20 per share which gives you a trailing P.E. of 59. The analyist that I follow is showing 97 at $.30 and 98 at $.48 with means a growth in EPS above 30% for the next few years. The industry average is computed at -26.7 for 97 and -61.4 by Thomson Financial Service Research.

Regarding your comment about "a general market correction could devistate this stock." THRT's Beta is 1.17 with means that the stock pretty much mirrors the performance of the overall market. Most Biotech have a much higher Beta.

Regarding trends. Until recently the stock had been in an uptrend since September. The stock has shown some recent weakness but looks like it is finding support at current trading levels.

I hope that my comments are helpful.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News